Kenneth S. Bauer, Pharm.D., Ph.D. Assistant Professor
Department:
School of Pharmacy
UMGCC Research Program:
Experimental Therapeutics Program
Education/Training:
College Degree:
B.S., Pharmacy, University of Maryland
Ph.D., Clinical Pharmacology, University of Pittsburgh
Post Doctoral
Degree:
Pharm.D., Pharmacy, University of Pittsburgh
Contact
Information:
Mailing Address:
Allied Health Building
100 Penn Street, Suite 540
Baltimore, MD 21201
Email:
kbauer@som.umaryland.edu
Phone:
410-706-3274
Fax:
410-706-6580
Research Interests:
My clinical pharmacology research interest involves the pharmacokinetic and pharmacodynamic analysis of investigational anti-cancer agents in Phase I and Phase II clinical trials. The proper use of anticancer agents requires an explicit understanding of their clinical pharmacology. Thus my lab is responsible for developing pharmacokinetic/pharmacodynamic models to describe the relationship between dose, plasma concentrations, biologic response markers, clinical effect, and clinical toxicity. Through this understanding it is then possible to design appropriate regimens to maximize response while minimizing toxicity. In addition to the clinical pharmacokinetic properties my laboratory is also involved with better understanding the absorption (when applicable), distribution, and metabolism of the new anticancer agents. This is accomplished using a variety of cell culture as well as other in vitro or in vivo techniques including the use of cell uptake and transport studies, liver microsomal metabolism, and in vivo animal pharmacokinetic, distribution, and toxicology studies.
The laboratory is also keenly interested in the physiologic expression of the Breast Cancer Resistance Protein (BCRP/ABCG2) and its role in the absorption, distribution, and elimination of those drugs that are substrates for this transporter.
Publications:
Rudek MA, March CL, Bauer KS, Pluda JM, Figg WD. High-Performance Liquid Chromatography with Mass Spectrometry Detection for Quantitation COL-3, a Chemically Modified Tetracycline, in Human Plasma. J Pharm Biomed Anal. 2000;22(6):1003-1014.
Bauer KS, Lush RM, Rudek MA, Sausville EA, and Figg WD. A High-Performance Liquid Chromatography Method using Ultraviolet and Fluorescence Detection for the Quantitation of UCN-01 from Human Plasma and Saliva. Biomed Chromatogr. 2000;14(5):338-343.
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase I Trial of 72 hour Continuous Infusion UCN-01 (7-hydroxystaurosporine) in Patients with Refractory Neoplasms. J Clin Oncol 2001;19(8),2319-2333.
Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F, Kulpa V, Thompkins A, Noone M, Goldspiel B, Pluda J, Figg WD, Liotta LA. A Phase I Trial of CAI (Carboxyamido-triazole) and Paclitaxel for Relapsed Solid Tumors: Potential efficacy of the Combination, and Demonstration of Pharmacokinetic Interaction. Clin Cancer Res. 2001; 7(6):1600-1609.
Rudek MA, Bauer KS, Lush RM, Stinson S, Senderowicz AM, Headlee D, Hil K, Arbuck S, Feuer J, Murgo A, Sausville E, Figg WD. Clinical Pharmacology of Flavopiridol Following a 72-hour Continuous Infusion. Annals of Pharmacotherapy 2003; 37(10): 1369-1374.
Edelman MJ, Bauer K, Khanwani S, Tait N, Trepel J, Karp J, Echo D. Phase I and Pharmacokinetic Study of Tributyrin: An Oral Butyrate Prodrug. Cancer Chemother Pharmacol. 2003, 51(5):439-444.
Khurana M, Salama NN, Scott KR, Nemieboka N, Bauer K, Eddington ND. The Brain Uptake, Metabolism and Pharmacokinetics of E121, an Antiepileptic Enaminone Ester, after Intra-peritoneal Administration in Rats. Biopharmaceutics and Drug Disposition. 2003; 28(9): 397-407.
Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, and Ross DD. Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus Laevis. Molecular Pharmacology. 2003, 64: 1452-1462
Garimella TS, Ross DD, Bauer KS. High-performance liquid chromatography method for the quantitation of the Breast Cancer Resistance Protein (BCRP/ABCG2) inhibitor Fumitremorgin C (FTC) and its chemical analogues, in mouse plasma and tissues. Journal of Chromatography B. 2004; 807(2): 203-208.
Garimella1 TS, Ross DD, Eiseman JL, Mondick1 JT, Joseph E, Nakanishi T, Bates SE, Bauer KS. Plasma Pharmacokinetics and Tissue Distribution of the Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitor Fumitremorgin C (FTC) in SCID Mice Bearing T8 Tumors. Cancer Chemotherapy and Pharmacology. 2005; 55(2):101-109.
